Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1207 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Tucatinib with trastuzumab emtansine for treating unresectable, locally advanced or metastatic HER2 positive breast cancer	Trastuzumab Emtansine (Kadcyla; T-DM1; PRO132365) , Tucatinib (ONT-380)	Breast cancer	Breast Cancer	2022	View \| Download
Tucatinib with trastuzumab for treating colorectal cancer	Trastuzumab (Herceptin; RG-597) , Tucatinib (ONT-380)	Colorectal cancer	Gastrointestinal Cancer	2022	View \| Download
Tusamitamab Ravtansine for previously treated advanced Non-Small-Cell Lung Cancer	Tusamitamab ravtansine (SAR408701)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2021	View \| Download
Ublituximab (TG-1101) in combination with umbralisib (TGR-1202) for chronic lymphocytic leukaemia	Ublituximab (TG-1101; LFB-R603) , Umbralisib (TGR-1202; RP-5264)	Chronic lymphocytic leukaemia (CLL)	Haematological Cancer and Lymphomas	2017	View \| Download
Ublituximab for treating multiple sclerosis	Ublituximab (TG-1101; LFB-R603)	Multiple sclerosis (MS)	Neurology	2022	View \| Download
Ublituximab in Combination with Ibrutinib for High Risk Chronic Lymphocytic Leukaemia	Ibrutinib (Imbruvica) , Ublituximab (TG-1101; LFB-R603)	Chronic lymphocytic leukaemia (CLL)	Haematological Cancer and Lymphomas	2018	View \| Download
Udenafil for congenital heart disease in adolescents after fontan palliation	Udenafil (Zydena; DA8159; ME-3113; WC-3043; WC-3055)	Congenital heart disease	Cardiovascular System	2018	View \| Download
Upadacitinib for active psoriatic arthritis with inadequate response to biological or non-biological DMARDs	Upadacitinib (ABT-494; Rinvoq; upadacitinib hemihydrate)	Psoriatic arthritis	Dermatology , Rheumatology	2019	View \| Download
Upadacitinib for Adults with Moderate to Severe Active Rheumatoid Arthritis After Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (DMARDs) or Biologic DMARDs Failure	Upadacitinib (ABT-494; Rinvoq; upadacitinib hemihydrate)	Rheumatoid arthritis	Rheumatology	2017	View \| Download
Upadacitinib for Ankylosing Spondylitis	Upadacitinib (ABT-494; Rinvoq; upadacitinib hemihydrate)	Ankylosing spondylitis	Musculoskeletal System	2020	View \| Download